[go: up one dir, main page]

DE602005012380D1 - 4-(5-(aminomethyl)-indol-1-ylmethyl)benzamidderivate und verwandte verbindungen als opioidrezeptorantagonisten zur behandlung von fettleibigkeit - Google Patents

4-(5-(aminomethyl)-indol-1-ylmethyl)benzamidderivate und verwandte verbindungen als opioidrezeptorantagonisten zur behandlung von fettleibigkeit

Info

Publication number
DE602005012380D1
DE602005012380D1 DE602005012380T DE602005012380T DE602005012380D1 DE 602005012380 D1 DE602005012380 D1 DE 602005012380D1 DE 602005012380 T DE602005012380 T DE 602005012380T DE 602005012380 T DE602005012380 T DE 602005012380T DE 602005012380 D1 DE602005012380 D1 DE 602005012380D1
Authority
DE
Germany
Prior art keywords
treatment
receptor antagonists
opioid receptor
indol
ylmethyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE602005012380T
Other languages
English (en)
Inventor
Dana Rae Benesh
Maria-Jesus Blanco-Pillado
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eli Lilly and Co
Original Assignee
Eli Lilly and Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eli Lilly and Co filed Critical Eli Lilly and Co
Publication of DE602005012380D1 publication Critical patent/DE602005012380D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D209/00Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04Indoles; Hydrogenated indoles
    • C07D209/08Indoles; Hydrogenated indoles with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to carbon atoms of the hetero ring
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10Drugs for genital or sexual disorders; Contraceptives for impotence
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32Alcohol-abuse
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34Tobacco-abuse
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00General protective or antinoxious agents
    • A61P39/02Antidotes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/06Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Addiction (AREA)
  • Psychiatry (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Endocrinology (AREA)
  • Hospice & Palliative Care (AREA)
  • Child & Adolescent Psychology (AREA)
  • Urology & Nephrology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Ophthalmology & Optometry (AREA)
  • Toxicology (AREA)
  • Reproductive Health (AREA)
  • Pain & Pain Management (AREA)
  • Otolaryngology (AREA)
  • Vascular Medicine (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
DE602005012380T 2004-03-15 2005-03-09 4-(5-(aminomethyl)-indol-1-ylmethyl)benzamidderivate und verwandte verbindungen als opioidrezeptorantagonisten zur behandlung von fettleibigkeit Expired - Lifetime DE602005012380D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US55317604P 2004-03-15 2004-03-15
PCT/US2005/007702 WO2005090303A1 (en) 2004-03-15 2005-03-09 4- (5- (aminomethyl) -indole-1-ylmethyl) -benzamide derivatives and related compounds as opioid receptor antagonists for the treatment of obesity

Publications (1)

Publication Number Publication Date
DE602005012380D1 true DE602005012380D1 (de) 2009-03-05

Family

ID=34962172

Family Applications (1)

Application Number Title Priority Date Filing Date
DE602005012380T Expired - Lifetime DE602005012380D1 (de) 2004-03-15 2005-03-09 4-(5-(aminomethyl)-indol-1-ylmethyl)benzamidderivate und verwandte verbindungen als opioidrezeptorantagonisten zur behandlung von fettleibigkeit

Country Status (8)

Country Link
US (1) US8088800B2 (de)
EP (1) EP1751103B1 (de)
JP (1) JP2007529523A (de)
AT (1) ATE420858T1 (de)
CA (1) CA2558030A1 (de)
DE (1) DE602005012380D1 (de)
ES (1) ES2318472T3 (de)
WO (1) WO2005090303A1 (de)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0314308B8 (pt) * 2002-09-19 2021-05-25 Lilly Co Eli antagonistas de opióide, seus usos, e composição farmacêutica
US8278442B2 (en) 2007-05-22 2012-10-02 Prosidion Limited Bicyclic aryl and heteroaryl compounds for the treatment of metabolic disorders
WO2009030962A1 (en) 2007-09-07 2009-03-12 Prosidion Limited Bicyclic aryl and heteroaryl receptor modulators
AU2009206653B2 (en) * 2008-01-22 2013-07-18 Eli Lilly And Company Kappa selective opioid receptor antagonist
MA34591B1 (fr) 2010-10-06 2013-10-02 Glaxosmithkline Llc Dérivés de benzimidazole utilisés comme inhibiteurs de pi3 kinase
ES2631607T3 (es) 2011-12-09 2017-09-01 Research Triangle Institute, International 4-Arilpiperazinas 1-sustituidas como antagonistas del receptor opioide kappa
EP2844259A4 (de) * 2012-04-30 2015-11-11 Anderson Gaweco Ror-modulatoren und deren verwendungen
WO2018053222A1 (en) 2016-09-16 2018-03-22 Research Traingle Institute Tetrahydroisoquinoline kappa opioid antagonists
US12161622B2 (en) 2021-05-04 2024-12-10 Janssen Pharmaceuticals, Inc. Compositions and methods for the treatment of depression
CN119156211A (zh) 2022-03-07 2024-12-17 杨森制药公司 用于治疗重性抑郁障碍的多晶型形式的阿替卡普兰
EP4489730A1 (de) 2022-03-07 2025-01-15 Janssen Pharmaceuticals, Inc. Zusammensetzungen mit atikaprant

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ197441A (en) * 1980-06-18 1984-11-09 May & Baker Ltd 2-or 3-(higher alkyl)-1h-indol(in)-(4 to 7)-yl-carboxylic acids and esters thereof
WO2002051805A1 (de) * 2000-12-27 2002-07-04 Bayer Aktiengesellschaft Indol-derivate
DK1379239T3 (da) 2001-03-29 2008-01-07 Lilly Co Eli N(2-aryl-ethyl)-benzyl-aminer som antagonister af 5 HT6 receptoren
ATE308522T1 (de) * 2002-05-30 2005-11-15 Lilly Co Eli Opioidrezeptorantagonisten
BRPI0314308B8 (pt) 2002-09-19 2021-05-25 Lilly Co Eli antagonistas de opióide, seus usos, e composição farmacêutica
MXPA05009367A (es) 2003-03-07 2005-11-04 Lilly Co Eli Antagonistas del receptor opioide.
ES2294475T3 (es) 2003-03-07 2008-04-01 Eli Lilly And Company Derivados de nicotinamida g-sustituidos como antagonistas de receptores de opioides.
WO2005061442A1 (en) 2003-12-12 2005-07-07 Eli Lilly And Company Opioid receptor antagonists
EP1699783B1 (de) 2003-12-22 2012-07-25 Eli Lilly And Company Antagonisten des opioidrezeptors
EP1727788B1 (de) 2004-03-12 2010-07-28 Eli Lilly And Company Antagonisten des opioidrezeptors
WO2005090337A1 (en) 2004-03-12 2005-09-29 Eli Lilly And Company Opioid receptor antagonists
EP1735268B1 (de) 2004-03-15 2012-02-15 Eli Lilly And Company Antagonisten des opioidrezeptors

Also Published As

Publication number Publication date
US8088800B2 (en) 2012-01-03
JP2007529523A (ja) 2007-10-25
US20070155793A1 (en) 2007-07-05
EP1751103A1 (de) 2007-02-14
ES2318472T3 (es) 2009-05-01
EP1751103B1 (de) 2009-01-14
ATE420858T1 (de) 2009-01-15
CA2558030A1 (en) 2005-09-29
WO2005090303A1 (en) 2005-09-29

Similar Documents

Publication Publication Date Title
NO20083480L (no) Piperidinoylpyrrolidiner som melanokortin type 4 reseptor agonister
AR064735A1 (es) Agonistas de gpcr y composicion farmaceutica en base al compuesto
PE20090775A1 (es) Nuevos derivados de biarilo
ATE463495T1 (de) Oxadiazolylpyrazolopyrimidine als mglur2- antagonisten
EA200870358A1 (ru) 2-(циклический амино) пиримидоновые производные в качестве ингибиторов tpk1
DE602005012380D1 (de) 4-(5-(aminomethyl)-indol-1-ylmethyl)benzamidderivate und verwandte verbindungen als opioidrezeptorantagonisten zur behandlung von fettleibigkeit
PE20071321A1 (es) Bencensulfonil-cromano, tiocromano, tetrahidronaftaleno e inhibidores de gamma secretasa relacionados
DE602005008558D1 (de) Kondensierte heterocyclische verbindungen und deren verwendung als antagonisten des metabotropen reznkungen
PE20120798A1 (es) Potentes inhibidores de molecula pequena de autofagia
ECSP055987A (es) Derivados de heteroarilcarbamoilbenceno
NO20076480L (no) Fenyl-3-{(3-(1H-pyrrol-2-yl)-[1,2,4]oksadiazol-5-yl]piperidin-1-yl} metanonderivater og beslektede forbindelser som positive allosteriske modulatorer av metatrofe glutamatreseptorer
PE20090886A1 (es) Nuevos inhibidores de quinasa
TW200633991A (en) Chemical compounds
PE20141120A1 (es) Compuestos heterociclicos
MY139750A (en) Cyclohexylamides as dopamine d3, d2 and 5ht1a antagonists
ATE464286T1 (de) Cyclopropanderivate und ihre pharmazeutische verwendung
PE20090482A1 (es) Derivados heterociclicos como antagonistas del receptor ccr2
PE20090601A1 (es) Derivados de piridin-il-oxi-piridinas como inhibidores de alk5
NO20080157L (no) Fremgangsmate for syntese av organiske forbindelser
PE20140868A1 (es) Antagonistas trpm8 y su uso en tratamientos
PE20140610A1 (es) Derivados de la piperidina 3-espirociclica como agonistas de receptores de la ghrelina
ATE466853T1 (de) Cgrp-rezeptorantagonisten
PE20081665A1 (es) Antagonistas del receptor de dopamina 2 de rapida disociacion
PE20120063A1 (es) Derivados de ciclopropilamida dirigidos contra el receptor de histamina h3
MX2007007428A (es) Compuestos heterociclicos, antagonistas de ccr2b.

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8328 Change in the person/name/address of the agent

Representative=s name: KROHER, STROBEL RECHTS- UND PATENTANWAELTE, 80336

8328 Change in the person/name/address of the agent

Representative=s name: DR. SCHOEN & PARTNER, 80336 MUENCHEN